Alnylam Pharma's Patisiran Phase 2 Study Decreases Neuropathy Progression

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) Tuesday reported a mean 2.5 point decrease in modified Neuropathy Impairment Score for 12-month clinical data from its ongoing Phase 2 open-label extension study with Patisiran. The investigational RNAi therapeutic is intended for the treatment of transthyretin -mediated amyloidosis in patients with familial amyloidotic polyneuropathy.

Patisiran was also found to be generally well tolerated out to 17 months of drug administration, with no drug-related serious adverse events to date. Alnylam is also planning to report 18-month OLE data in late 2015.

These new clinical data are being presented at the 67th Annual Meeting of the American Academy of Neurology. This decrease in neuropathy progression compares favorably to the 13 to 18 point increase in mNIS+7 in untreated patients with similar baseline characteristics.

The company said it is actively enrolling FAP patients around the world for the APOLLO Phase 3 study.